default author photo

Shengxiang Ren

Tongji University - Department of Medical Oncology

Professor

No. 507, Zheng Min Road

Shanghai, Shanghai

China

  • Tongji University - Department of Medical Oncology

    • Email
    • Tel: +86-21- 65115006
    • Fax: +86-21-65111298
SCHOLARLY PAPERS

5

DOWNLOADS

447

TOTAL CITATIONS

3

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Clinical Characteristics of Pregnant Women with Coronavirus Disease 2019 in Wuhan, China

Number of pages: 25 Posted: 25 Mar 2020
Biheng Cheng, Tao Jiang, Lu Zhang, Ruheng Hu, Jinhua Tian, Yan Jiang, Bo Huang, Jun Li, Min Wei, Jing Yang, Shengxiang Ren and Gaohua Wang
Wuhan University - Department of Obstetrics, Tongji University - Department of Medical Oncology, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Wuhan University - Department of Obstetrics, Tongji University - Department of Medical Oncology and Wuhan University - Department of Psychiatry
Downloads 250 (304,988)
Citation 3

Abstract:

Loading...

COVID-2019; Pregnant Women; Clinical Characteristics; Severity

2.

Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial

Number of pages: 19 Posted: 05 Feb 2024
Jia Yu, Anwen Xiong, Lei Wang, Xinlong Zheng, Tao Jiang, Qi Wang, Bin Chen, Menghang Yang, Wei Li, Jiajia Yuan, Changhong Zhao, Xiaohui Chen, Caicun Zhou and Shengxiang Ren
Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Fujian Medical University - Fujian Medical University Cancer Hospital, Tongji University - Department of Oncology, Tongji University - Shanghai Pulmonary Hospital, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Fujian Medical University - Department of Thoracic Surgery, Tongji University - Department of Medical Oncology and Tongji University - Department of Medical Oncology
Downloads 86 (765,566)

Abstract:

Loading...

Camrelizumab, Nab-paclitaxel, Immunotherapy, ES-SCLC

3.

Front-Line Treatment for Advanced Non-Small-Cell Lung Cancer and ALK Fusion: A Network Meta-Analysis

Number of pages: 29 Posted: 27 Sep 2021
Yaokai Wen, Tao Jiang, Xiangrong Wu, Haoxin Peng, Shengxiang Ren and Caicun Zhou
Tongji University, Tongji University - Department of Medical Oncology, Guangzhou Medical University, Peking University - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Tongji University - Department of Medical Oncology and Tongji University - Department of Medical Oncology
Downloads 54 (1,020,567)

Abstract:

Loading...

anaplastic lymphoma kinase, front-line therapy, non-small-cell lung cancer, network meta-analysis.

4.

Heterogeneity of Neoantigen Landscape Between Primary Lesions and Their Matched Metastases in Lung Cancer

Number of pages: 26 Posted: 17 Dec 2019
Tao Jiang, Chunxia Su, Ruirui Cheng, Yuanwei Pan, Henghui Zhang, Ji He, Ying He, Renhong Tang, Shengxiang Ren and Caicun Zhou
Tongji University - Department of Medical Oncology, Tongji University - Department of Medical Oncology, Zhengzhou University, Zhengzhou University, Beijing Genecast Biotechnology Co., Beijing Genecast Biotechnology Co., Shanghai Hengrui Pharmaceutical Co., LTD, Shanghai Hengrui Pharmaceutical Co., LTD, Tongji University - Department of Medical Oncology and Tongji University - Department of Medical Oncology
Downloads 41 (1,170,409)

Abstract:

Loading...

lung cancer; metastasis; neoantigen

5.

Consolidative Ablation Plus Third-Generation EGFR-TKIs Improves Survival in Advanced NSCLC Patients With Oligo-Residual Disease

Number of pages: 42 Posted: 03 Jun 2026
Jizhong Yin, Xinlong Zheng, Junhong Guo, Qiyu Fang, Shen Chen, Shuo Yang, Aiwu Li, Guanghui Gao, Jia Yu, Menghang Yang, Tao Jiang, Sha Zhao, Xiaozhen Liu, Lingyun Ye, Chenlei Cai, Zhengcao Xing, Xinyu Liu, Jiayi Zhu, Yan Zhang, Xiaoxia Chen, Fengyin Wu, Lei Wang, Bin Chen and Shengxiang Ren
Government of the People's Republic of China - Shanghai Changzheng Hospital, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology and Tongji University - Department of Medical Oncology
Downloads 16 (1,590,289)

Abstract:

Loading...

Non-small cell lung cancer (NSCLC), EGFR-Tyrosine kinase inhibitors (TKIs), Oligo-residual disease (ORD), Consolidative ablation